Biologic effects and potential clinical applications of Flt3 ligand

Current Opinion in Hematology

Volumn 5, Issue 3, 1998, Pages 192-196

  Lyman, Stewart D ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GROWTH FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; LIGAND; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR;

CELL MOTILITY; CELL PROLIFERATION; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031877978     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199805000-00008     Document Type: Short Survey

References (62)

1. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FF, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP: Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993, 75:1157-1167.
2. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ: Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994, 83:2795-2801.
3. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Keiner G, Namikawa R, Rennick D, Roncarolo M-G, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F: Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994, 368:643-648.
4. Rosnet O, Mattei MG, Marchetto S, Birnbaum D: Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991, 9:380-385.
5. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D: Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogens 1991, 6:1641-1650.
6. Rosnet O, Schiff C, Pébusque M-J, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993, 82:1110-1119.
7. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991, 65:1143-1152.
8. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 1994, 91:459-463.
9. Lyman SD, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S: Structural analysis of human and murine flt3 ligand genomic loci. Oncogene 1995, 11:1165-1172.
10. Lyman SD: Biology of flt3 ligand and receptor. Int J Hematol 1995, 62:63-73.
11. Lyman SD, Brasel K, Rousseau AM, Williams DE: The flt3 ligand: A hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells 1994, 12:99-107.
12. Namikawa R, Muench MO, Roncarolo MG: Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells 1996, 14:388-395.
13. Lyman SD, Jacobsen SEW: c-kit Ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91:1101-1134. The most comprehensive review on the biology of Flt3 ligand, and the only one to thoroughly compare the biological activities of Flt3 ligand and c-kit ligand.
14. Namikawa R, Muench MO, de Vries JE, Roncarolo MG: The FLK2/FLT3 ligand synergies with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 1996, 87:1881-1890.
15. Lemieux ME, Chappel SM, Miller CL, Eaves CJ: Differential ability of flt3-ligand, interleukin-11, and Steel factor to support the generation of B cell progenitors and myeloid cells from primitive murine fetal liver cells. Exp Hematol 1997, 25:951-957.
16. Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SEW: The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential: Suppression of apoptosis and counteraction by TNF-α and TGF-β. J Immunol 1996, 157:2953-2960.
17. Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R: FltS ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996, 26:1504-1510.
18. Hunte BE, Hudak S, Campbell D, Xu Y, Rennick D: flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J Immunol 1996, 156:489-496.
19. + blood progenitors for anticancer therapy. Exp Hematol 1995, 23:1463-1471.
20. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996, 184:1953-1962. This paper not only demonstrates the capacity of Flt3 ligand to generate dendritic cells in vivo, it also provides a careful phenotyping of these cells and reveals the presence of different populations of dendritic cells.
21. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD: Hematologic effects of flt3 ligand in vivo in mice. Blood 1996, 88:2004-2012. The effects of Flt3 ligand administration in mice on various blood lineages are well documented.
22. McKenna HJ, Miller RE, Brasel KE, Maraskovsky E, Maliszewski C, Pulendran B, Lynch D, Teepe M, Roux ER, Smith J, Williams DE, Lyman SD, Peschon JJ, Stocking K: Targeted disruption of the flt3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells, B lymphocytes, and dendritic cells. Blood (Suppl 1) 1996, 88:474a.
23. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995, 3:147-161.
24. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
25. Hjertson M, Sundström C, Lyman SD, Nilsson K, Nilsson G: Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Exp Hematol 1996, 24:748-754.
26. Pharr PN, Hofbauer A: Loss of flk-2/flt3 expression during commitment of multipotent mouse hematopoietic progenitor cells to the mast cell lineage. Exp Hematol 1997, 25:620-628.
27. Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes L, Rennick D: FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 1995, 85:2747-2755.
28. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski CR, Maraskovsky E: Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 1997, 159:2222-2231.
29. Winton EF, Bucur SZ, Bray PA, Toba K, Williams DE, McClure HM, Lyman SD: The hematopoietic effects of recombinant human (rh) Flt3 ligand administered to non-human primates. Blood (Suppl 1) 1995, 86:424a.
30. Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I: Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997, 89:3998-4004.
31. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997, 3:625-631. First published report on the antitumor effects of Flt3 ligand in vivo. This paper includes an analysis of the immune cells that are responsible for the antitumor effect.
32. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K: Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 1997, 57:3511-3516. The data in this paper illustrate that Flt3 ligand has antitumor effects not only when injected directly in vivo, but also when it is expressed by the tumor cells themselves.
33. Sonpavde G, Braun S, Chen K, Lyman S, Cornetta K: Efficacy of flt3-ligand in a murine leukemia model. Blood 1997, 90:187a.
34. Juan TS, McNiece IK, Van G, Lacey D, Hartley C, McElroy P, Sun Y, Argento J, Hill D, Yan XQ, Reicher FA: Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 1997, 90:76-84.
35. Lyman SD, Williams DE: Biology and potential clinical applications of flt3 ligand. Curr Opin Hematol 1995, 2:177-181.
36. Brasel K, McKenna HJ, Charrier K, Morrissey PJ, Williams DE, Lyman SD: Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997, 90:3781-3788. This paper illustrates the tremendous synergy between Flt3 ligand and other cytokines to mobilize a variety of colony-forming cells to the peripheral blood of mice. It also shows that cells mobilized with Flt3 ligand alone give long-term reconstitution of all hematopoietic lineages.
37. Papayannopoulou T, Nakamoto B, Andrews RG, Lyman SD, Lee MY: In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 1997, 90:620-629.
38. + cell mobilization to blood in rhesus monkeys. Blood 1996, 88(Suppl 1):642a.
39. Maraskovsky E, Roux E, Teepe M, Braddy S, Hoek J, Lebsack M, McKenna HJ: Flt3 ligand increases peripheral blood dendritic cells in healthy volunteers. Blood 1997, 90:580a.
40. Koller MR, Oxender M, Brott DA, Palsson BØ: flt-3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion. J Hematother 1996, 5:449-459.
41. Kogler G, Callejas J, Hakenberg P, Enczmann J, Adams O, Daubener W, Krempe C, Gobel U, Somville T, Wernet P: Hematopoietic transplant potential of unrelated cord blood: Critical issues. J Hematother 1996, 5:105-116.
42. -) human hematopoietic cells: Novel responses to Flt3-ligand and thrombopoietin. J Exp Med 1996, 183:2551-2558.
43. Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ: Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci U S A 1996, 93:1470-1474.
44. Bertolini F, Battaglia M, Pedrazzoli P, Da Prada GA, Lanza A, Soligo D, Caneva L, Sarina B, Murphy S, Thomas T, della Cuna GR: Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997, 89:2679-2688.
45. Schain LR, Jain S, Wysocki M, Hall M, Dadey B, Pennathurdas R, Biddle W, Wolf J, Okarma TB, Lebkowski JS: Animal serum-free culture of purified human CD34+ cells: Amplification of progenitors from G-CSF and GM-CSF-Mobilized peripheral blood. J Hematother 1997, 6:335-349.
46. Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring HJ, Simmons PJ: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood 1997, 90:2260-2272. A mechanistic sludy of how Flt3 ligand works in expanding cells ex vivo.
47. + cells ex vivo for as long as 6 months.
48. + hematopoietic progenitor cells. Blood 1995, 86:3413-3420.
49. Nordon RE, Ginsberg SS, Eaves CJ: High-resolution cell division tracking demonstrates the Flt3-ligand-dependence of human marrow CD34(+)CD38(-) cell production in vitro. Br J Haematol 1997, 98:528-539.
50. Zandstra PW, Conneally E, Petzer AL, Piret JM, Eaves CJ: Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A 1997, 94:4698-4703.
51. + cells in culture.
52. Elwood NJ, Zogos H, Willson T, Begley CG: Retroviral transduction of human progenitor cells: Use of granulocyte colony-stimulating factor plus stem cell factor to mobilize progenitor cells in vivo and stimulation by Flt3/Flk-2 ligand in vitro. Blood 1996, 88:4452-4462.
53. + cord blood cells under serum-free conditions. Hum Gene Ther 1997, 8:1651-1658.
54. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10:4239-4242.
55. Crooks GM, Kohn DB: Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells. Blood 1993, 82:3290-3297.
56. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
57. Caux C, Liu YJ, Banchereau J: Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995, 16:2-4.
58. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997, 186:1183-1187.
59. Drakes ML, Lu L, Subbotin VM, Thomson AW: In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol 1997, 159:4268-4278.
60. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT: FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997, 179:174-184.
61. Strobl H, Bello-Fernandez C, Riedl E, Pickl WF, Majdic O, Lyman SD, Knapp W: flt3 ligand in cooperation with transforming growth factor-β1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 1997, 90:1425-1434.
62. Lebsack ME, McKenna HJ, Hoek JA, Hanna R, Feng A, Maraskovsky E, Hayes FA: Safety of flt3 ligand in healthy volunteers. Blood 1997, 90:170a.